Shanghai Pharmaceuticals Joins hands with the Secondary Military Medical University to Explore the New Medicine R&D and Translational Medicine Field

HONG KONG, July 31, 2013 /PRNewswire/ -- Nowadays, Translational Medicine has become the buzzword in the field of pharmaceutical research and development. To jointly promote the development of this emerging field of research, Shanghai Pharmaceuticals Holding Co., Ltd. ("Shanghai Pharmaceuticals" or the "Company" and, together with its subsidiaries, the "Group; stock code: 601607.SH; 2607.HK), today announce that the Company entered into a strategic framework cooperation agreement with the Secondary Military Medical University ("SMMU"), namely "SMMU - Shanghai Pharmaceuticals Translational Medicine Alliance". Pursuant to the agreement, Shanghai Pharmaceutical will provide a certain amount of R&D fund input annually for the establishment of advance of "SMMU - Shanghai Pharmaceutical Translational Medicine Alliance" to carry out R&D cooperation in fields of new medicine and medical devices development and so forth.

It is expected that through this research strategic cooperation, Shanghai Pharmaceuticals can drew on the integrated resources combining translational medicine, pharmaceutical research, clinical and affiliated hospital of SMMU, to enhance R&D efficiency and accelerate new product launch in the market. Meanwhile, SMMU can make use of Shanghai Pharmaceuticals' sufficient experience in the research and development of drugs, its solid industrial foundation and extensive sales network to accelerate the transformation of scientific research and launch new drugs into the market to meet clinical needs. Both sides will give full play to their respective advantages, expand the depth of diversified cooperation and achieve win-win situation in the future.

This cooperation is funded by Shanghai Pharmaceuticals to support the development of major innovative health products that possess a certain research foundation, with potential protection of intellectual property rights and developmental feasibility, which are undertaken by the professional team at the SMMU for The joint alliance of translational medicine can fully exercise the advantages of Shanghai Pharmaceuticals as well as the University's to further promote the cooperation between the military and civilians, and R&D on major innovative products, so as to accelerate the transformation of scientific research outcomes.

Upon the new management team's taking office, Shanghai Pharmaceuticals continues to adhere to its trademark of scientific and technological innovation, striving to maintain an open R&D model with an emphasis on translational medicine applications through collecting social innovative resources, exploring the integrative model of "Production, Academy and Research" and forming long term partnership with financially strong research institutes and universities. Shanghai Pharmaceuticals has established innovative R&D collaboration with many distinctive institutes such as Shanghai Institute of Materia Medica, China Pharmaceutical University, Shenyang Pharmaceutical University, Zhejian University and Shanghai Jiao Tong University, with a total amount reached over RMB 200 million; the Group also invested RMB 180 million on 4 collaborative drug research projects with Fudan-ZhangJiang in 2011, which greatly enriched Shanghai Pharmaceuticals 's R&D product chain.

About The Second Military Medical University

The Second Military Medical University is the primary institute for the national "Project 211" and military "Project 2110"; it holds the only research base in military that can train all levels of medical agents in the military and has jurisdiction over three national Tier 3 Grade A hospitals; pharmacy first-degree is a national key academic discipline. The University now holds 1 State Key Laboratory, 1 Education Key Laboratory, 13 Military Key Laboratories, 5 dual-academicians and received a total of 196 military level (including provincial level) science and technology achievement awards including the State Preeminent Science and Technology Award, a recognition on the institute's outstanding achievements in the field of innovation research and development.

About Shanghai Pharmaceuticals Holding Co., Ltd.

Shanghai Pharmaceuticals is the only integrated pharmaceutical company in the PRC that has leading positions in both pharmaceutical product and distribution markets. It was China's second-largest pharmaceutical distributor and third-largest pharmaceutical producer. The Group adopts an integrated vertical business model and provides solutions in pharmaceutical manufacturing, distribution, logistics storage and retail. The Group currently offers more than 800 pharmaceutical products as well as pharmaceutical distribution and supply chain solutions to more than 8,000 hospitals and medical institutions in China. The Group also operates approximately 1,700 self-operated and franchise stores nationwide.

For further information, please contact:

Porda Havas International Finance Communications Group 
Kelly Fung +852 3150 6763 
Angie An +852 3150 6736 
Kannie Lam +852 3150 6721 
Christine Tai +852 3150 6776 
Fax: +852 3150 6728
Source: Shanghai Pharmaceuticals Holding Co., Ltd.
Related Stocks:
HongKong:2607 Shanghai:601607